Katherine N. Weilbaecher, M.D.

Perez EA, Weilbaecher K
Aromatase inhibitors and bone loss.
Oncology (Williston Park) 2006 Aug;20(9):1029-39; discussion 1039-40

Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.
Clin Cancer Res 2006 Oct 15;12(20 Pt 2):6209s-6212s

Hirbe A, Morgan EA, Uluckan O, Weilbaecher K
Skeletal complications of breast cancer therapies.
Clin Cancer Res 2006 Oct 15;12(20 Pt 2):6309s-6314s

Hirbe A, Morgan E, Uluckan O, Weilbaecher K
Skeletal Complications of Breast and Prostate Cancer Therapies.
In: Favus MJ (ed), Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 6th ed., ASBMR, Washington, DC, USA, pp 390-395 (2006)

Mohla S, Weilbaecher KN, Cher M, Oyajobi B, Van Poznak C, and D Clohisy
Third North American Symposium on Skeletal Complications of Malignancy: Summary of the Scientific Sessions.
Cancer 2003; 97(3 Supplement):719-725

Weilbaecher KN
Mechanisms of osteoporosis after hematopoietic cell transplantation.
Biol Blood Marrow Transplant 2000;6(2A):165-74